Chantix Varenicline Tablets Recalled for N-Nitroso Impurity
Pfizer is recalling specific lots of Chantix (varenicline) 1 mg tablets nationwide due to the presence of N-nitroso-varenicline impurity above FDA's acceptable interim intake limit. The affected lots were distributed nationwide.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II recall involving a manufacturing deviation (CGMP deviation) with a chemical impurity above acceptable limits. The source text does not report any illnesses, injuries, or hospitalizations associated with this impurity, and the hazard is related to manufacturing process control rather than an immediate health threat. Class II recalls without reported harm typically score 2 per the rubric.
Plain-English summary
Pfizer Inc. is recalling specific lots of Chantix (varenicline tartrate) 1 mg tablets (56-tablet packages) distributed nationwide. The recall was initiated because these lots contain the impurity N-nitroso-varenicline at levels exceeding FDA's acceptable interim intake limit.
The affected lots include: 00018777, 00019289, 00019593, 00019682, 00019846, 00019977, 00020295, 00020448, 00020458, 00020480, 00021024, 00021073, 00021074, CW1565, CW1566, CW1567, CW1568, CW1569, CW1570, CW1571, CW1572, CW1573, CW1574, CW1575, CW1578, CW1579, CW1581, DF5277, DF5278, DF5279, DF5280, DF5281, DF5282, DR5086, DR5092, DR5093, DR5094, DT3885, DW4148, DW4152, DY7987, EC9841, EC9842, EC9847, EC9848, EE1011, EM1069, EM1070, EN5694, EN5695, EP1717, EP1718, EP1719, EW2012, EW3854, EW3865, EX2102, EX2103, with expiration dates between September 2021 and December 2023. The product is manufactured in Ireland and distributed by Pfizer Labs (Division of Pfizer Inc., New York, NY).
Consumers who have a recalled lot of Chantix should consult their healthcare provider or pharmacist before discontinuing use. This is a Class II recall.
The recalled product
- Product
- CHANTIX (VARENICLINE TARTRATE)
- Brand
- CHANTIX
- Manufacturer
- Pfizer Inc.
- Hazard
- chemical-impurity
- manufacturing-deviation
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Lots 00018777
- 00019289
- 00019593
- 00019682
- 00019846
- 00019977
- 00020295
- 00020448
- 00020458
- 00020480
- 00021024
- 00021073
- 00021074
- CW1565
- CW1566
- CW1567
- CW1568
- CW1569
- CW1570
- CW1571
UPCs (3)
- 0300690469560
- 0300690468563
- 0300690471280
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · CHANTIX
- ModeratePfizer recalls Chantix tablets for N-nitroso-varenicline impurity
FDA (Drugs) · 2021-09-29
- ModeratePfizer Chantix Tablets Recalled for N-nitroso-varenicline Impurity
FDA (Drugs) · 2021-08-11
- ModeratePfizer Chantix Tablets Recalled for Nitroso Impurity Above FDA Limit
FDA (Drugs) · 2021-08-11
- ModeratePfizer Chantix Tablets Recalled for N-Nitroso-Varenicline Impurity
FDA (Drugs) · 2021-08-11
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- HighBeak & Skiff Alcohol Antiseptic Sanitizer recalled for acetaldehyde contamination
FDA (Drugs) · 2026-06-17
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- SevereCIMZIA injection recalled due to lack of sterility assurance
FDA (Drugs) · 2026-05-27